依瑞奈单抗治疗丹麦三叉神经痛患者的安全性和疗效:一项双盲、随机、安慰剂对照的概念验证研究
这项在丹麦进行的双盲随机安慰剂对照概念验证研究纳入80例三叉神经痛患者,评估依瑞奈单抗140 mg皮下注射的疗效。结果显示4周时应答者比例在依瑞奈单抗组为35%(14/40),安慰剂组为45%(18/40),组间无差异(估计效应量-10%,95%CI -31至11;p=0.36)。两组不良事件发生率均为50%,依瑞奈单抗未减少疼痛强度。
要点
- 依瑞奈单抗140 mg皮下注射4周后应答者比例与安慰剂无差异(35% vs 45%,p=0.36)。
- 依瑞奈单抗组和安慰剂组不良事件发生率均为50%,最常见为便秘和头痛。
- 作者认为CGRP在三叉神经痛的阵发性疼痛中可能不起重要作用,仍需耐受良好的有效治疗。
核心结论
- 依瑞奈单抗与安慰剂相比未减少三叉神经痛患者的疼痛强度,CGRP在三叉神经痛的阵发性疼痛中可能不起重要作用,仍需耐受良好的有效治疗。
研究设计与样本
- 在丹麦哥本哈根大学医院丹麦头痛中心进行的随机、双盲、安慰剂对照试验,纳入18-85岁特发性或经典三叉神经痛成人患者,按1:1随机接受依瑞奈单抗140 mg或安慰剂皮下注射,随访4周,在意向治疗人群分析。
主要发现
- 意向治疗人群中,4周时应答者数量在依瑞奈单抗组为14/40(35%),安慰剂组为18/40(45%),估计效应量-10%(95%CI -31至11;p=0.36)。
- 依瑞奈单抗组40例中20例(50%)报告不良事件,安慰剂组40例中20例(50%)报告不良事件。
- 依瑞奈单抗组最常见不良事件为便秘(28%)和头痛(10%),安慰剂组为头痛(13%)、便秘(10%)和腹痛(10%)。
关键数值与推荐
- 应答者定义为随访期间平均每日疼痛强度较基线期降低至少30%的患者。
- 纳入标准包括11点数字评定量表自报疼痛强度至少4分,且每日至少3次疼痛发作。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab modulates sensory processing in peripheral trigeminal pain pathways in mice and was reported to be effective for patients with trigeminal neuralgia in open-label studies. We aimed to evaluate the efficacy of erenumab in patients with trigeminal neuralgia. METHODS: We did a randomised, double-blind, placebo-controlled trial in adults (aged 18-85 years) with idiopathic or classic trigeminal neuralgia as defined by the 3rd edition of the International Classification of Headache Disorders. The trial was based at the Danish Headache Center, Copenhagen University Hospital. Eligible participants had no clinically significant cerebrovascular or cardiovascular disease, had self-reported pain intensity of at least 4 on the 11-point Numeric Rating Scale (0=no pain, 10=worst pain imaginable), and had at least three daily pain paroxysms. After a 1-week pre-screening period, patients entered a 4-week baseline period. Participants who met pain inclusion criteria at the end of the baseline period were randomly assigned (1:1) to receive subcutaneous injections of either erenumab 140 mg or placebo and entered the 4-week follow-up period. Randomisation was done in blocks of 10 using a computer-generated schedule by a third-party company. Participants and assessors were masked to treatment allocation, and erenumab and placebo were packed in identical prefilled syringes. The primary outcome was the number of responders, defined as patients who had a reduction of at least 30% in mean average daily pain intensity during the follow-up period compared with during the baseline period, analysed in the intention-to-treat population. This trial is registered with the European Union Drug Regulating Authorities Clinical Trials Database, EudraCT number 2019-000848-95. FINDINGS: We assessed 860 patients for suitability and excluded 741 between Oct 28, 2019, and Sept 13, 2021. 119 participants entered a 1-week pre-screening period and 26 were excluded, 93 participants entered a 4-week baseline period with 13 excluded before randomisation, and 80 participants were randomly assigned to erenumab 140 mg (n=40) or placebo (n=40). There was no difference between groups in the number of responders at 4 weeks in the intention-to-treat population (14 [35%] of 40 with erenumab vs 18 [45%] of 40 with placebo; estimated effect size -10% [95% CI -31 to 11]; p=0·36). 20 (50%) of 40 participants reported adverse events in each group. The most common adverse events were constipation (28%) and headache (10%) in the erenumab group, and headache (13%), constipation (10%), and abdominal pain (10%) in the placebo group. INTERPRETATION: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain. Well tolerated, effective treatments in trigeminal neuralgia are still needed. FUNDING: Novartis.
引用
- Schott Andersen AS, Maarbjerg S, Noory N, et al. Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol. 2022. PMID: 36113495. doi:10.1016/S1474-4422(22)00294-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。